Nervgen Pharma Corp (NGEN.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 14 | 14 | 14 | 14 | 16 |
| Accounts receivable | 263 | -247 | 237 | 82 | -409 |
| Other Working Capital | -193 | -299 | 794 | 356 | 743 |
| Other Operating Activity | -6,482 | -4,786 | -4,709 | -4,570 | -4,010 |
| Operating Cash Flow | $-6,397 | $-5,318 | $-3,665 | $-4,119 | $-3,660 |
| Cash Flows From Investing Activities | |||||
| Purchase Sale Intangibles | 25 | N/A | N/A | 25 | 25 |
| Other Investing Activity | 25 | 25 | 25 | 25 | 25 |
| Investing Cash Flow | $25 | $25 | $25 | $25 | $25 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -25 | -25 | -25 | -25 | -25 |
| Common Stock Issued | 14,110 | 0 | 1,134 | 1,640 | 0 |
| Other Financing Activity | 2,657 | 1,020 | 3,643 | -340 | 335 |
| Financing Cash Flow | $16,742 | $995 | $4,752 | $1,274 | $310 |
| Exchange Rate Effect | 336 | -13 | 91 | 23 | -416 |
| Beginning Cash Position | 11,364 | 15,675 | 14,471 | 17,267 | 21,008 |
| End Cash Position | 22,070 | 11,364 | 15,675 | 14,471 | 17,267 |
| Net Cash Flow | $10,370 | $-4,298 | $1,113 | $-2,819 | $-3,325 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,397 | -5,318 | -3,665 | -4,119 | -3,660 |
| Free Cash Flow | -6,397 | -5,318 | -3,665 | -4,119 | -3,660 |